PCSK9, His, Cynomolgus
PCSK9, His, Cynomolgus

Immobilized PCSK9, His, Cynomolgus, His Tag at 5 μg /ml(100 μl /well) on the plate. Dose response curve for Anti-PCSK9 Antibody, hFc Tag with the EC50 of 88.7ng/ml determined by ELISA.

PCSK9, His, Cynomolgus

The purity of PCSK9, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

PCSK9, His, Cynomolgus

PCSK9, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PCSK9, His, Cynomolgus

Cynomolgus LDLR, His Tag immobilized on CM5 Chip can bind PCSK9, His, Cynomolgus, His Tag with an affinity constant of 0.27 nM as determined in SPR assay (Biacore T200).

PCSK9, His, Cynomolgus

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Z04891
¥63,425.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
PCSK9 (Glu151-Gln811)
Accession # A0A2K5TZC4		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight the pro-form (59 kDa) and mature form (14 kDa)
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • PCSK9, His, Cynomolgus
    • PCSK9, His, Cynomolgus

    Immobilized PCSK9, His, Cynomolgus, His Tag at 5 μg /ml(100 μl /well) on the plate. Dose response curve for Anti-PCSK9 Antibody, hFc Tag with the EC50 of 88.7ng/ml determined by ELISA.

  • PCSK9, His, Cynomolgus
    • PCSK9, His, Cynomolgus

    The purity of PCSK9, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • PCSK9, His, Cynomolgus
    • PCSK9, His, Cynomolgus

    PCSK9, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • PCSK9, His, Cynomolgus
    • PCSK9, His, Cynomolgus

    Cynomolgus LDLR, His Tag immobilized on CM5 Chip can bind PCSK9, His, Cynomolgus, His Tag with an affinity constant of 0.27 nM as determined in SPR assay (Biacore T200).


Background
Target Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Synonyms PCSK9

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.